Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 10/20 | 0.51 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.31 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.31 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844480 | 0.89 | SLC5A2 (0.43) | SLC5A2SLC5A1HCRTR1HCRTR2ADRB2 | |
| SCHEMBL12776465 | 0.87 | SLC5A2 (0.51) | SLC5A2SLC5A1NAMPTHCRTR1HCRTR2 | |
| SCHEMBL12844478 | 0.85 | SLC5A2 (0.51) | SLC5A2SLC5A1HCRTR1HCRTR2ADRB2 | |
| SCHEMBL14545123 | 0.84 | SLC5A2 (0.58) | SLC5A2SLC5A1NAMPTHCRTR1HCRTR2 | |
| SCHEMBL14401353 | 0.83 | SLC5A2 (0.46) | SLC5A2SLC5A1HCRTR1HCRTR2ADRB2 | |
| SCHEMBL12309864 | 0.81 | SLC5A2 (0.59) | SLC5A2SLC5A1 | |
| SCHEMBL12257458 | 0.78 | SLC5A2 (0.51) | SLC5A2SLC5A1NAMPTHCRTR1HCRTR2 | |
| SCHEMBL12336858 | 0.77 | SLC5A2 (0.47) | SLC5A2SLC5A1 | |
| SCHEMBL12257578 | 0.76 | SLC5A2 (0.71) | SLC5A2SLC5A1 | |
| SCHEMBL14049006 | 0.76 | SLC5A2 (0.49) | SLC5A2SLC5A1NAMPTADRB2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910619-B2 | e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | SLC5A1, SLC5A2, SLC5A11 | SLC5A2 2/4885SLC5A1 1/4885NAMPT 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.